nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomefloxacin—TOP2A—Epirubicin—liver cancer	0.318	0.446	CbGbCtD
Lomefloxacin—TOP2A—Doxorubicin—liver cancer	0.169	0.237	CbGbCtD
Lomefloxacin—ABCC2—Sorafenib—liver cancer	0.114	0.16	CbGbCtD
Lomefloxacin—ABCC2—Doxorubicin—liver cancer	0.0693	0.0973	CbGbCtD
Lomefloxacin—ABCC2—bile canaliculus—liver cancer	0.0622	0.625	CbGeAlD
Lomefloxacin—CYP1A2—Sorafenib—liver cancer	0.0426	0.0598	CbGbCtD
Lomefloxacin—ABCC2—bile duct—liver cancer	0.0194	0.195	CbGeAlD
Lomefloxacin—ABCC2—bile—liver cancer	0.0149	0.15	CbGeAlD
Lomefloxacin—ABCC2—liver—liver cancer	0.00121	0.0122	CbGeAlD
Lomefloxacin—SLC22A5—liver—liver cancer	0.000941	0.00945	CbGeAlD
Lomefloxacin—CYP1A2—liver—liver cancer	0.000853	0.00857	CbGeAlD
Lomefloxacin—TOP2A—Idarubicin—Epirubicin—liver cancer	0.000822	0.173	CbGdCrCtD
Lomefloxacin—TOP2A—Daunorubicin—Epirubicin—liver cancer	0.000822	0.173	CbGdCrCtD
Lomefloxacin—TOP2A—Doxorubicin—Epirubicin—liver cancer	0.000822	0.173	CbGdCrCtD
Lomefloxacin—TOP2A—Idarubicin—Doxorubicin—liver cancer	0.000761	0.16	CbGdCrCtD
Lomefloxacin—TOP2A—Epirubicin—Doxorubicin—liver cancer	0.000761	0.16	CbGdCrCtD
Lomefloxacin—TOP2A—Daunorubicin—Doxorubicin—liver cancer	0.000761	0.16	CbGdCrCtD
Lomefloxacin—Skin exfoliation—Epirubicin—liver cancer	0.000472	0.00357	CcSEcCtD
Lomefloxacin—Shock—Sorafenib—liver cancer	0.000469	0.00355	CcSEcCtD
Lomefloxacin—Thrombocytopenia—Sorafenib—liver cancer	0.000467	0.00353	CcSEcCtD
Lomefloxacin—Vaginal infection—Epirubicin—liver cancer	0.000466	0.00353	CcSEcCtD
Lomefloxacin—Blood urea increased—Epirubicin—liver cancer	0.000466	0.00353	CcSEcCtD
Lomefloxacin—Skin disorder—Sorafenib—liver cancer	0.000463	0.0035	CcSEcCtD
Lomefloxacin—Hiccups—Doxorubicin—liver cancer	0.000457	0.00346	CcSEcCtD
Lomefloxacin—Vaginal inflammation—Doxorubicin—liver cancer	0.000457	0.00346	CcSEcCtD
Lomefloxacin—Pulmonary embolism—Doxorubicin—liver cancer	0.000457	0.00346	CcSEcCtD
Lomefloxacin—Anorexia—Sorafenib—liver cancer	0.000455	0.00344	CcSEcCtD
Lomefloxacin—Cramps of lower extremities—Epirubicin—liver cancer	0.000454	0.00343	CcSEcCtD
Lomefloxacin—Coma—Epirubicin—liver cancer	0.000451	0.00341	CcSEcCtD
Lomefloxacin—Influenza like illness—Doxorubicin—liver cancer	0.000444	0.00336	CcSEcCtD
Lomefloxacin—Pulmonary oedema—Epirubicin—liver cancer	0.00044	0.00333	CcSEcCtD
Lomefloxacin—Candida infection—Doxorubicin—liver cancer	0.000436	0.0033	CcSEcCtD
Lomefloxacin—Skin exfoliation—Doxorubicin—liver cancer	0.000436	0.0033	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000435	0.00329	CcSEcCtD
Lomefloxacin—Hypertonia—Epirubicin—liver cancer	0.000433	0.00327	CcSEcCtD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.000432	0.00854	CbGpPWpGaD
Lomefloxacin—Vaginal infection—Doxorubicin—liver cancer	0.000432	0.00326	CcSEcCtD
Lomefloxacin—Blood urea increased—Doxorubicin—liver cancer	0.000432	0.00326	CcSEcCtD
Lomefloxacin—Abnormal vision—Epirubicin—liver cancer	0.000431	0.00326	CcSEcCtD
Lomefloxacin—Mental disability—Epirubicin—liver cancer	0.000429	0.00324	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000427	0.00843	CbGpPWpGaD
Lomefloxacin—Dyspnoea—Sorafenib—liver cancer	0.000425	0.00322	CcSEcCtD
Lomefloxacin—Lymphadenopathy—Epirubicin—liver cancer	0.00042	0.00318	CcSEcCtD
Lomefloxacin—Cramps of lower extremities—Doxorubicin—liver cancer	0.00042	0.00318	CcSEcCtD
Lomefloxacin—Dyspepsia—Sorafenib—liver cancer	0.00042	0.00317	CcSEcCtD
Lomefloxacin—Coma—Doxorubicin—liver cancer	0.000418	0.00316	CcSEcCtD
Lomefloxacin—Phlebitis—Epirubicin—liver cancer	0.000416	0.00315	CcSEcCtD
Lomefloxacin—Decreased appetite—Sorafenib—liver cancer	0.000415	0.00313	CcSEcCtD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000414	0.00818	CbGpPWpGaD
Lomefloxacin—Fatigue—Sorafenib—liver cancer	0.000411	0.00311	CcSEcCtD
Lomefloxacin—Hepatic function abnormal—Epirubicin—liver cancer	0.00041	0.0031	CcSEcCtD
Lomefloxacin—Photosensitivity—Epirubicin—liver cancer	0.000408	0.00309	CcSEcCtD
Lomefloxacin—Constipation—Sorafenib—liver cancer	0.000408	0.00308	CcSEcCtD
Lomefloxacin—Pulmonary oedema—Doxorubicin—liver cancer	0.000407	0.00308	CcSEcCtD
Lomefloxacin—Vascular purpura—Epirubicin—liver cancer	0.000401	0.00303	CcSEcCtD
Lomefloxacin—Hypertonia—Doxorubicin—liver cancer	0.000401	0.00303	CcSEcCtD
Lomefloxacin—Eczema—Epirubicin—liver cancer	0.000399	0.00302	CcSEcCtD
Lomefloxacin—Abnormal vision—Doxorubicin—liver cancer	0.000399	0.00301	CcSEcCtD
Lomefloxacin—Eye pain—Epirubicin—liver cancer	0.000397	0.003	CcSEcCtD
Lomefloxacin—Mental disability—Doxorubicin—liver cancer	0.000397	0.003	CcSEcCtD
Lomefloxacin—Gastrointestinal pain—Sorafenib—liver cancer	0.00039	0.00295	CcSEcCtD
Lomefloxacin—Lymphadenopathy—Doxorubicin—liver cancer	0.000389	0.00294	CcSEcCtD
Lomefloxacin—Phlebitis—Doxorubicin—liver cancer	0.000385	0.00291	CcSEcCtD
Lomefloxacin—Hot flush—Epirubicin—liver cancer	0.000383	0.0029	CcSEcCtD
Lomefloxacin—Increased appetite—Epirubicin—liver cancer	0.000382	0.00289	CcSEcCtD
Lomefloxacin—Dermatitis exfoliative—Epirubicin—liver cancer	0.00038	0.00287	CcSEcCtD
Lomefloxacin—Menopausal symptoms—Epirubicin—liver cancer	0.00038	0.00287	CcSEcCtD
Lomefloxacin—Hepatic function abnormal—Doxorubicin—liver cancer	0.00038	0.00287	CcSEcCtD
Lomefloxacin—Urticaria—Sorafenib—liver cancer	0.000379	0.00286	CcSEcCtD
Lomefloxacin—Photosensitivity—Doxorubicin—liver cancer	0.000378	0.00286	CcSEcCtD
Lomefloxacin—Abdominal pain—Sorafenib—liver cancer	0.000377	0.00285	CcSEcCtD
Lomefloxacin—Dermatitis bullous—Epirubicin—liver cancer	0.000375	0.00284	CcSEcCtD
Lomefloxacin—Purpura—Epirubicin—liver cancer	0.000372	0.00281	CcSEcCtD
Lomefloxacin—Vascular purpura—Doxorubicin—liver cancer	0.000371	0.0028	CcSEcCtD
Lomefloxacin—Anaphylactoid reaction—Epirubicin—liver cancer	0.000371	0.0028	CcSEcCtD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—CTNNB1—liver cancer	0.00037	0.00732	CbGpPWpGaD
Lomefloxacin—Eczema—Doxorubicin—liver cancer	0.000369	0.00279	CcSEcCtD
Lomefloxacin—Eye pain—Doxorubicin—liver cancer	0.000368	0.00278	CcSEcCtD
Lomefloxacin—Cardiac failure—Epirubicin—liver cancer	0.000368	0.00278	CcSEcCtD
Lomefloxacin—Hypoglycaemia—Epirubicin—liver cancer	0.000368	0.00278	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—CYP1A1—liver cancer	0.000367	0.00725	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.000364	0.00719	CbGpPWpGaD
Lomefloxacin—CYP1A2—Xenobiotics—CYP2E1—liver cancer	0.000362	0.00715	CbGpPWpGaD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000359	0.0071	CbGpPWpGaD
Lomefloxacin—Diplopia—Epirubicin—liver cancer	0.000359	0.00271	CcSEcCtD
Lomefloxacin—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000359	0.00271	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000357	0.00705	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000357	0.00705	CbGpPWpGaD
Lomefloxacin—Hot flush—Doxorubicin—liver cancer	0.000355	0.00268	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—GSTA3—liver cancer	0.000354	0.007	CbGpPWpGaD
Lomefloxacin—Increased appetite—Doxorubicin—liver cancer	0.000353	0.00267	CcSEcCtD
Lomefloxacin—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000352	0.00266	CcSEcCtD
Lomefloxacin—Menopausal symptoms—Doxorubicin—liver cancer	0.000352	0.00266	CcSEcCtD
Lomefloxacin—Hypersensitivity—Sorafenib—liver cancer	0.000351	0.00266	CcSEcCtD
Lomefloxacin—CYP1A2—Tamoxifen metabolism—CYP2E1—liver cancer	0.000348	0.00687	CbGpPWpGaD
Lomefloxacin—Dermatitis bullous—Doxorubicin—liver cancer	0.000347	0.00263	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—UGDH—liver cancer	0.000347	0.00686	CbGpPWpGaD
Lomefloxacin—Face oedema—Epirubicin—liver cancer	0.000346	0.00262	CcSEcCtD
Lomefloxacin—CYP1A2—Aflatoxin activation and detoxification—GGT1—liver cancer	0.000346	0.00683	CbGpPWpGaD
Lomefloxacin—Purpura—Doxorubicin—liver cancer	0.000344	0.0026	CcSEcCtD
Lomefloxacin—Gatifloxacin—ALB—liver cancer	0.000344	0.599	CrCbGaD
Lomefloxacin—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000343	0.00259	CcSEcCtD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000343	0.00677	CbGpPWpGaD
Lomefloxacin—Asthenia—Sorafenib—liver cancer	0.000342	0.00259	CcSEcCtD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000342	0.00676	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.000342	0.00676	CbGpPWpGaD
Lomefloxacin—Hypoglycaemia—Doxorubicin—liver cancer	0.00034	0.00257	CcSEcCtD
Lomefloxacin—Cardiac failure—Doxorubicin—liver cancer	0.00034	0.00257	CcSEcCtD
Lomefloxacin—Pruritus—Sorafenib—liver cancer	0.000337	0.00255	CcSEcCtD
Lomefloxacin—Ataxia—Epirubicin—liver cancer	0.000337	0.00255	CcSEcCtD
Lomefloxacin—Blood creatinine increased—Epirubicin—liver cancer	0.000336	0.00254	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—PPARA—liver cancer	0.000335	0.00663	CbGpPWpGaD
Lomefloxacin—Diplopia—Doxorubicin—liver cancer	0.000332	0.00251	CcSEcCtD
Lomefloxacin—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000332	0.00251	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—PSMD10—liver cancer	0.000326	0.00645	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—PSMA4—liver cancer	0.000326	0.00645	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Sorafenib—liver cancer	0.000326	0.00247	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—GSTA4—liver cancer	0.000324	0.00641	CbGpPWpGaD
Lomefloxacin—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000323	0.00244	CcSEcCtD
Lomefloxacin—Face oedema—Doxorubicin—liver cancer	0.00032	0.00242	CcSEcCtD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—liver cancer	0.000317	0.00627	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—GSTA2—liver cancer	0.000316	0.00624	CbGpPWpGaD
Lomefloxacin—Dizziness—Sorafenib—liver cancer	0.000315	0.00238	CcSEcCtD
Lomefloxacin—Ataxia—Doxorubicin—liver cancer	0.000312	0.00236	CcSEcCtD
Lomefloxacin—Blood creatinine increased—Doxorubicin—liver cancer	0.000311	0.00235	CcSEcCtD
Lomefloxacin—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000311	0.00614	CbGpPWpGaD
Lomefloxacin—Dysphagia—Epirubicin—liver cancer	0.00031	0.00234	CcSEcCtD
Lomefloxacin—Eosinophilia—Epirubicin—liver cancer	0.000307	0.00232	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.000306	0.00606	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—GSTA1—liver cancer	0.000305	0.00602	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—AHR—liver cancer	0.000305	0.00602	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—ESR1—liver cancer	0.000304	0.006	CbGpPWpGaD
Lomefloxacin—Vomiting—Sorafenib—liver cancer	0.000303	0.00229	CcSEcCtD
Lomefloxacin—Angina pectoris—Epirubicin—liver cancer	0.000302	0.00228	CcSEcCtD
Lomefloxacin—Rash—Sorafenib—liver cancer	0.000301	0.00227	CcSEcCtD
Lomefloxacin—Dermatitis—Sorafenib—liver cancer	0.0003	0.00227	CcSEcCtD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—MYC—liver cancer	0.0003	0.00593	CbGpPWpGaD
Lomefloxacin—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000299	0.00226	CcSEcCtD
Lomefloxacin—Headache—Sorafenib—liver cancer	0.000299	0.00226	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.000299	0.0059	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen metabolism—GSTM1—liver cancer	0.000298	0.00589	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.000293	0.0058	CbGpPWpGaD
Lomefloxacin—Dysuria—Epirubicin—liver cancer	0.00029	0.00219	CcSEcCtD
Lomefloxacin—Dysphagia—Doxorubicin—liver cancer	0.000287	0.00217	CcSEcCtD
Lomefloxacin—Eosinophilia—Doxorubicin—liver cancer	0.000284	0.00215	CcSEcCtD
Lomefloxacin—Nausea—Sorafenib—liver cancer	0.000283	0.00214	CcSEcCtD
Lomefloxacin—Photosensitivity reaction—Epirubicin—liver cancer	0.000283	0.00214	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.000283	0.00559	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen metabolism—CYP1A1—liver cancer	0.000283	0.00558	CbGpPWpGaD
Lomefloxacin—Hyperglycaemia—Epirubicin—liver cancer	0.00028	0.00211	CcSEcCtD
Lomefloxacin—Angina pectoris—Doxorubicin—liver cancer	0.000279	0.00211	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.000277	0.00548	CbGpPWpGaD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000276	0.00545	CbGpPWpGaD
Lomefloxacin—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000274	0.00207	CcSEcCtD
Lomefloxacin—Renal failure—Epirubicin—liver cancer	0.000272	0.00205	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Epirubicin—liver cancer	0.000271	0.00205	CcSEcCtD
Lomefloxacin—Stomatitis—Epirubicin—liver cancer	0.000269	0.00204	CcSEcCtD
Lomefloxacin—Conjunctivitis—Epirubicin—liver cancer	0.000269	0.00203	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—NFE2L2—liver cancer	0.000269	0.00531	CbGpPWpGaD
Lomefloxacin—Dysuria—Doxorubicin—liver cancer	0.000268	0.00203	CcSEcCtD
Lomefloxacin—Haematuria—Epirubicin—liver cancer	0.000264	0.00199	CcSEcCtD
Lomefloxacin—Photosensitivity reaction—Doxorubicin—liver cancer	0.000262	0.00198	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000261	0.00515	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000261	0.00515	CbGpPWpGaD
Lomefloxacin—Epistaxis—Epirubicin—liver cancer	0.000261	0.00197	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.000261	0.00515	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.000261	0.00515	CbGpPWpGaD
Lomefloxacin—CYP1A2—Xenobiotics—CYP1A1—liver cancer	0.00026	0.00513	CbGpPWpGaD
Lomefloxacin—Hyperglycaemia—Doxorubicin—liver cancer	0.000259	0.00196	CcSEcCtD
Lomefloxacin—Agranulocytosis—Epirubicin—liver cancer	0.000258	0.00195	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—GPX3—liver cancer	0.000256	0.00506	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—TGFA—liver cancer	0.000256	0.00506	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.000254	0.00502	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.000254	0.00502	CbGpPWpGaD
Lomefloxacin—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000254	0.00192	CcSEcCtD
Lomefloxacin—Bradycardia—Epirubicin—liver cancer	0.000253	0.00191	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—SERPINA1—liver cancer	0.000252	0.00499	CbGpPWpGaD
Lomefloxacin—Renal failure—Doxorubicin—liver cancer	0.000251	0.0019	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Doxorubicin—liver cancer	0.000251	0.0019	CcSEcCtD
Lomefloxacin—CYP1A2—Tamoxifen metabolism—CYP1A1—liver cancer	0.00025	0.00494	CbGpPWpGaD
Lomefloxacin—Stomatitis—Doxorubicin—liver cancer	0.000249	0.00188	CcSEcCtD
Lomefloxacin—Rhinitis—Epirubicin—liver cancer	0.000249	0.00188	CcSEcCtD
Lomefloxacin—Conjunctivitis—Doxorubicin—liver cancer	0.000249	0.00188	CcSEcCtD
Lomefloxacin—Hepatitis—Epirubicin—liver cancer	0.000248	0.00188	CcSEcCtD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—TP53—liver cancer	0.000246	0.00487	CbGpPWpGaD
Lomefloxacin—Pharyngitis—Epirubicin—liver cancer	0.000246	0.00186	CcSEcCtD
Lomefloxacin—Haematuria—Doxorubicin—liver cancer	0.000244	0.00184	CcSEcCtD
Lomefloxacin—Epistaxis—Doxorubicin—liver cancer	0.000241	0.00182	CcSEcCtD
Lomefloxacin—Visual impairment—Epirubicin—liver cancer	0.000239	0.00181	CcSEcCtD
Lomefloxacin—Agranulocytosis—Doxorubicin—liver cancer	0.000239	0.0018	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000236	0.00467	CbGpPWpGaD
Lomefloxacin—Erythema multiforme—Epirubicin—liver cancer	0.000235	0.00177	CcSEcCtD
Lomefloxacin—Bradycardia—Doxorubicin—liver cancer	0.000234	0.00177	CcSEcCtD
Lomefloxacin—Tinnitus—Epirubicin—liver cancer	0.000231	0.00175	CcSEcCtD
Lomefloxacin—Flushing—Epirubicin—liver cancer	0.00023	0.00174	CcSEcCtD
Lomefloxacin—Norfloxacin—CYP1A1—liver cancer	0.00023	0.401	CrCbGaD
Lomefloxacin—Rhinitis—Doxorubicin—liver cancer	0.00023	0.00174	CcSEcCtD
Lomefloxacin—Hepatitis—Doxorubicin—liver cancer	0.00023	0.00174	CcSEcCtD
Lomefloxacin—Pharyngitis—Doxorubicin—liver cancer	0.000228	0.00172	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.000228	0.0045	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000223	0.00442	CbGpPWpGaD
Lomefloxacin—Chills—Epirubicin—liver cancer	0.000223	0.00168	CcSEcCtD
Lomefloxacin—Arrhythmia—Epirubicin—liver cancer	0.000222	0.00168	CcSEcCtD
Lomefloxacin—Visual impairment—Doxorubicin—liver cancer	0.000221	0.00167	CcSEcCtD
Lomefloxacin—Erythema multiforme—Doxorubicin—liver cancer	0.000217	0.00164	CcSEcCtD
Lomefloxacin—Tinnitus—Doxorubicin—liver cancer	0.000214	0.00162	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—HPGDS—liver cancer	0.000213	0.00421	CbGpPWpGaD
Lomefloxacin—Flushing—Doxorubicin—liver cancer	0.000213	0.00161	CcSEcCtD
Lomefloxacin—Flatulence—Epirubicin—liver cancer	0.000213	0.00161	CcSEcCtD
Lomefloxacin—Tension—Epirubicin—liver cancer	0.000212	0.0016	CcSEcCtD
Lomefloxacin—Dysgeusia—Epirubicin—liver cancer	0.000212	0.0016	CcSEcCtD
Lomefloxacin—Nervousness—Epirubicin—liver cancer	0.00021	0.00159	CcSEcCtD
Lomefloxacin—Back pain—Epirubicin—liver cancer	0.000209	0.00158	CcSEcCtD
Lomefloxacin—Muscle spasms—Epirubicin—liver cancer	0.000208	0.00157	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—PCNA—liver cancer	0.000206	0.00408	CbGpPWpGaD
Lomefloxacin—Chills—Doxorubicin—liver cancer	0.000206	0.00156	CcSEcCtD
Lomefloxacin—Arrhythmia—Doxorubicin—liver cancer	0.000205	0.00155	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—UGDH—liver cancer	0.000203	0.00401	CbGpPWpGaD
Lomefloxacin—Ill-defined disorder—Epirubicin—liver cancer	0.0002	0.00152	CcSEcCtD
Lomefloxacin—Anaemia—Epirubicin—liver cancer	0.0002	0.00151	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTA3—liver cancer	0.000199	0.00394	CbGpPWpGaD
Lomefloxacin—Agitation—Epirubicin—liver cancer	0.000198	0.0015	CcSEcCtD
Lomefloxacin—Flatulence—Doxorubicin—liver cancer	0.000197	0.00149	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—JUN—liver cancer	0.000197	0.00389	CbGpPWpGaD
Lomefloxacin—Tension—Doxorubicin—liver cancer	0.000196	0.00148	CcSEcCtD
Lomefloxacin—Dysgeusia—Doxorubicin—liver cancer	0.000196	0.00148	CcSEcCtD
Lomefloxacin—Malaise—Epirubicin—liver cancer	0.000195	0.00147	CcSEcCtD
Lomefloxacin—Nervousness—Doxorubicin—liver cancer	0.000194	0.00147	CcSEcCtD
Lomefloxacin—Vertigo—Epirubicin—liver cancer	0.000194	0.00147	CcSEcCtD
Lomefloxacin—Syncope—Epirubicin—liver cancer	0.000194	0.00146	CcSEcCtD
Lomefloxacin—Leukopenia—Epirubicin—liver cancer	0.000193	0.00146	CcSEcCtD
Lomefloxacin—Back pain—Doxorubicin—liver cancer	0.000193	0.00146	CcSEcCtD
Lomefloxacin—CYP1A2—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000193	0.00381	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.000192	0.0038	CbGpPWpGaD
Lomefloxacin—Muscle spasms—Doxorubicin—liver cancer	0.000192	0.00145	CcSEcCtD
Lomefloxacin—Loss of consciousness—Epirubicin—liver cancer	0.00019	0.00144	CcSEcCtD
Lomefloxacin—Cough—Epirubicin—liver cancer	0.000188	0.00143	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.000187	0.0037	CbGpPWpGaD
Lomefloxacin—Convulsion—Epirubicin—liver cancer	0.000187	0.00141	CcSEcCtD
Lomefloxacin—Hypertension—Epirubicin—liver cancer	0.000186	0.00141	CcSEcCtD
Lomefloxacin—CYP1A2—Tryptophan metabolism—CYP2E1—liver cancer	0.000186	0.00367	CbGpPWpGaD
Lomefloxacin—Ill-defined disorder—Doxorubicin—liver cancer	0.000185	0.0014	CcSEcCtD
Lomefloxacin—Anaemia—Doxorubicin—liver cancer	0.000185	0.0014	CcSEcCtD
Lomefloxacin—Chest pain—Epirubicin—liver cancer	0.000184	0.00139	CcSEcCtD
Lomefloxacin—Myalgia—Epirubicin—liver cancer	0.000184	0.00139	CcSEcCtD
Lomefloxacin—Arthralgia—Epirubicin—liver cancer	0.000184	0.00139	CcSEcCtD
Lomefloxacin—Agitation—Doxorubicin—liver cancer	0.000184	0.00139	CcSEcCtD
Lomefloxacin—Anxiety—Epirubicin—liver cancer	0.000183	0.00139	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000183	0.00361	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTA4—liver cancer	0.000182	0.0036	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000182	0.0036	CbGpPWpGaD
Lomefloxacin—Discomfort—Epirubicin—liver cancer	0.000182	0.00137	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—GGT1—liver cancer	0.00018	0.00356	CbGpPWpGaD
Lomefloxacin—Malaise—Doxorubicin—liver cancer	0.00018	0.00136	CcSEcCtD
Lomefloxacin—Dry mouth—Epirubicin—liver cancer	0.00018	0.00136	CcSEcCtD
Lomefloxacin—Vertigo—Doxorubicin—liver cancer	0.00018	0.00136	CcSEcCtD
Lomefloxacin—Syncope—Doxorubicin—liver cancer	0.000179	0.00136	CcSEcCtD
Lomefloxacin—Leukopenia—Doxorubicin—liver cancer	0.000179	0.00135	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTA2—liver cancer	0.000178	0.00351	CbGpPWpGaD
Lomefloxacin—Confusional state—Epirubicin—liver cancer	0.000178	0.00134	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Epirubicin—liver cancer	0.000176	0.00133	CcSEcCtD
Lomefloxacin—Oedema—Epirubicin—liver cancer	0.000176	0.00133	CcSEcCtD
Lomefloxacin—Loss of consciousness—Doxorubicin—liver cancer	0.000176	0.00133	CcSEcCtD
Lomefloxacin—Cough—Doxorubicin—liver cancer	0.000174	0.00132	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000174	0.00344	CbGpPWpGaD
Lomefloxacin—Shock—Epirubicin—liver cancer	0.000173	0.00131	CcSEcCtD
Lomefloxacin—Convulsion—Doxorubicin—liver cancer	0.000173	0.00131	CcSEcCtD
Lomefloxacin—Thrombocytopenia—Epirubicin—liver cancer	0.000173	0.0013	CcSEcCtD
Lomefloxacin—Hypertension—Doxorubicin—liver cancer	0.000173	0.0013	CcSEcCtD
Lomefloxacin—Tachycardia—Epirubicin—liver cancer	0.000172	0.0013	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.000172	0.00339	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.000171	0.00339	CbGpPWpGaD
Lomefloxacin—Skin disorder—Epirubicin—liver cancer	0.000171	0.00129	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Epirubicin—liver cancer	0.00017	0.00129	CcSEcCtD
Lomefloxacin—Chest pain—Doxorubicin—liver cancer	0.00017	0.00129	CcSEcCtD
Lomefloxacin—Arthralgia—Doxorubicin—liver cancer	0.00017	0.00129	CcSEcCtD
Lomefloxacin—Myalgia—Doxorubicin—liver cancer	0.00017	0.00129	CcSEcCtD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.00017	0.00336	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.00017	0.00335	CbGpPWpGaD
Lomefloxacin—Anxiety—Doxorubicin—liver cancer	0.00017	0.00128	CcSEcCtD
Lomefloxacin—Discomfort—Doxorubicin—liver cancer	0.000168	0.00127	CcSEcCtD
Lomefloxacin—Anorexia—Epirubicin—liver cancer	0.000168	0.00127	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000167	0.0033	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000167	0.0033	CbGpPWpGaD
Lomefloxacin—Dry mouth—Doxorubicin—liver cancer	0.000166	0.00126	CcSEcCtD
Lomefloxacin—Hypotension—Epirubicin—liver cancer	0.000165	0.00125	CcSEcCtD
Lomefloxacin—Confusional state—Doxorubicin—liver cancer	0.000164	0.00124	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.000164	0.00324	CbGpPWpGaD
Lomefloxacin—Anaphylactic shock—Doxorubicin—liver cancer	0.000163	0.00123	CcSEcCtD
Lomefloxacin—Oedema—Doxorubicin—liver cancer	0.000163	0.00123	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—GSTP1—liver cancer	0.000162	0.0032	CbGpPWpGaD
Lomefloxacin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000161	0.00121	CcSEcCtD
Lomefloxacin—Shock—Doxorubicin—liver cancer	0.00016	0.00121	CcSEcCtD
Lomefloxacin—ABCC2—NRF2 pathway—HMOX1—liver cancer	0.00016	0.00316	CbGpPWpGaD
Lomefloxacin—Thrombocytopenia—Doxorubicin—liver cancer	0.00016	0.00121	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.000159	0.00315	CbGpPWpGaD
Lomefloxacin—Insomnia—Epirubicin—liver cancer	0.000159	0.00121	CcSEcCtD
Lomefloxacin—Tachycardia—Doxorubicin—liver cancer	0.000159	0.0012	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.000158	0.00313	CbGpPWpGaD
Lomefloxacin—Skin disorder—Doxorubicin—liver cancer	0.000158	0.0012	CcSEcCtD
Lomefloxacin—Paraesthesia—Epirubicin—liver cancer	0.000158	0.0012	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000158	0.00312	CbGpPWpGaD
Lomefloxacin—Hyperhidrosis—Doxorubicin—liver cancer	0.000158	0.00119	CcSEcCtD
Lomefloxacin—Dyspnoea—Epirubicin—liver cancer	0.000157	0.00119	CcSEcCtD
Lomefloxacin—Somnolence—Epirubicin—liver cancer	0.000157	0.00118	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000156	0.00309	CbGpPWpGaD
Lomefloxacin—Anorexia—Doxorubicin—liver cancer	0.000155	0.00118	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000155	0.00307	CbGpPWpGaD
Lomefloxacin—Dyspepsia—Epirubicin—liver cancer	0.000155	0.00117	CcSEcCtD
Lomefloxacin—Decreased appetite—Epirubicin—liver cancer	0.000153	0.00116	CcSEcCtD
Lomefloxacin—Hypotension—Doxorubicin—liver cancer	0.000152	0.00115	CcSEcCtD
Lomefloxacin—Fatigue—Epirubicin—liver cancer	0.000152	0.00115	CcSEcCtD
Lomefloxacin—Constipation—Epirubicin—liver cancer	0.000151	0.00114	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.00015	0.00297	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—GSTM1—liver cancer	0.000149	0.00294	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—HGF—liver cancer	0.000149	0.00294	CbGpPWpGaD
Lomefloxacin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000149	0.00112	CcSEcCtD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000148	0.00293	CbGpPWpGaD
Lomefloxacin—Insomnia—Doxorubicin—liver cancer	0.000148	0.00112	CcSEcCtD
Lomefloxacin—Paraesthesia—Doxorubicin—liver cancer	0.000146	0.00111	CcSEcCtD
Lomefloxacin—Dyspnoea—Doxorubicin—liver cancer	0.000145	0.0011	CcSEcCtD
Lomefloxacin—Feeling abnormal—Epirubicin—liver cancer	0.000145	0.0011	CcSEcCtD
Lomefloxacin—Somnolence—Doxorubicin—liver cancer	0.000145	0.0011	CcSEcCtD
Lomefloxacin—Gastrointestinal pain—Epirubicin—liver cancer	0.000144	0.00109	CcSEcCtD
Lomefloxacin—Dyspepsia—Doxorubicin—liver cancer	0.000144	0.00109	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—PPARA—liver cancer	0.000143	0.00282	CbGpPWpGaD
Lomefloxacin—Decreased appetite—Doxorubicin—liver cancer	0.000142	0.00107	CcSEcCtD
Lomefloxacin—Fatigue—Doxorubicin—liver cancer	0.000141	0.00106	CcSEcCtD
Lomefloxacin—Urticaria—Epirubicin—liver cancer	0.00014	0.00106	CcSEcCtD
Lomefloxacin—Constipation—Doxorubicin—liver cancer	0.000139	0.00105	CcSEcCtD
Lomefloxacin—Abdominal pain—Epirubicin—liver cancer	0.000139	0.00105	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000137	0.00271	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—liver cancer	0.000136	0.0027	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000136	0.00268	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000135	0.00266	CbGpPWpGaD
Lomefloxacin—Feeling abnormal—Doxorubicin—liver cancer	0.000134	0.00102	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000133	0.00264	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000133	0.00264	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000133	0.00264	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000133	0.00264	CbGpPWpGaD
Lomefloxacin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000133	0.00101	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.000131	0.0026	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Epirubicin—liver cancer	0.00013	0.000982	CcSEcCtD
Lomefloxacin—Urticaria—Doxorubicin—liver cancer	0.00013	0.00098	CcSEcCtD
Lomefloxacin—Abdominal pain—Doxorubicin—liver cancer	0.000129	0.000975	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000128	0.00254	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000127	0.00252	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000127	0.00252	CbGpPWpGaD
Lomefloxacin—Asthenia—Epirubicin—liver cancer	0.000126	0.000956	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000125	0.00247	CbGpPWpGaD
Lomefloxacin—Pruritus—Epirubicin—liver cancer	0.000125	0.000943	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000122	0.00241	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000122	0.00241	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000122	0.00241	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1B—liver cancer	0.000121	0.00239	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Epirubicin—liver cancer	0.000121	0.000912	CcSEcCtD
Lomefloxacin—Hypersensitivity—Doxorubicin—liver cancer	0.00012	0.000909	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—PSMD10—liver cancer	0.00012	0.00237	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—PSMA4—liver cancer	0.00012	0.00237	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000119	0.00235	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—PPARG—liver cancer	0.000118	0.00233	CbGpPWpGaD
Lomefloxacin—Asthenia—Doxorubicin—liver cancer	0.000117	0.000885	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000117	0.00231	CbGpPWpGaD
Lomefloxacin—Dizziness—Epirubicin—liver cancer	0.000117	0.000881	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000115	0.00228	CbGpPWpGaD
Lomefloxacin—Pruritus—Doxorubicin—liver cancer	0.000115	0.000872	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—liver cancer	0.000115	0.00228	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000115	0.00227	CbGpPWpGaD
Lomefloxacin—Vomiting—Epirubicin—liver cancer	0.000112	0.000847	CcSEcCtD
Lomefloxacin—Diarrhoea—Doxorubicin—liver cancer	0.000112	0.000844	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—liver cancer	0.000111	0.0022	CbGpPWpGaD
Lomefloxacin—Rash—Epirubicin—liver cancer	0.000111	0.00084	CcSEcCtD
Lomefloxacin—Dermatitis—Epirubicin—liver cancer	0.000111	0.00084	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000111	0.00218	CbGpPWpGaD
Lomefloxacin—Headache—Epirubicin—liver cancer	0.00011	0.000835	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.000108	0.00213	CbGpPWpGaD
Lomefloxacin—Dizziness—Doxorubicin—liver cancer	0.000108	0.000815	CcSEcCtD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000108	0.00213	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—PSMA4—liver cancer	0.000107	0.00212	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—PSMD10—liver cancer	0.000107	0.00212	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000107	0.00211	CbGpPWpGaD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000106	0.0021	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—SERPINE1—liver cancer	0.000106	0.0021	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000105	0.00208	CbGpPWpGaD
Lomefloxacin—Nausea—Epirubicin—liver cancer	0.000105	0.000792	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000104	0.00206	CbGpPWpGaD
Lomefloxacin—Vomiting—Doxorubicin—liver cancer	0.000104	0.000784	CcSEcCtD
Lomefloxacin—Rash—Doxorubicin—liver cancer	0.000103	0.000778	CcSEcCtD
Lomefloxacin—Dermatitis—Doxorubicin—liver cancer	0.000103	0.000777	CcSEcCtD
Lomefloxacin—Headache—Doxorubicin—liver cancer	0.000102	0.000773	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000101	0.00201	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.0001	0.00198	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	9.99e-05	0.00197	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—NAT2—liver cancer	9.92e-05	0.00196	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	9.78e-05	0.00193	CbGpPWpGaD
Lomefloxacin—Nausea—Doxorubicin—liver cancer	9.69e-05	0.000733	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—liver cancer	9.24e-05	0.00183	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	9.15e-05	0.00181	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTP1—liver cancer	9.11e-05	0.0018	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	8.97e-05	0.00177	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	8.74e-05	0.00173	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	8.73e-05	0.00173	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	8.71e-05	0.00172	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	8.65e-05	0.00171	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	8.45e-05	0.00167	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTM1—liver cancer	8.37e-05	0.00166	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—JUN—liver cancer	8.36e-05	0.00165	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	8.32e-05	0.00164	CbGpPWpGaD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—ALB—liver cancer	8.27e-05	0.00163	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	8.24e-05	0.00163	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	8.2e-05	0.00162	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—H2AFX—liver cancer	8.09e-05	0.0016	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—CYCS—liver cancer	8.05e-05	0.00159	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—HPGDS—liver cancer	7.93e-05	0.00157	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—MAPK8—liver cancer	7.91e-05	0.00156	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	7.61e-05	0.0015	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—PCNA—liver cancer	7.57e-05	0.0015	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	7.51e-05	0.00148	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	7.51e-05	0.00148	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	7.35e-05	0.00145	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	7.33e-05	0.00145	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—H2AFX—liver cancer	7.23e-05	0.00143	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	7.15e-05	0.00141	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	7e-05	0.00138	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—HMOX1—liver cancer	7e-05	0.00138	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	6.99e-05	0.00138	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	6.93e-05	0.00137	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—PCNA—liver cancer	6.77e-05	0.00134	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—TERT—liver cancer	6.54e-05	0.00129	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	6.52e-05	0.00129	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	6.47e-05	0.00128	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP2E1—liver cancer	6.46e-05	0.00128	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	6.38e-05	0.00126	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	6.25e-05	0.00124	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—TGFB1—liver cancer	6.07e-05	0.0012	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	5.94e-05	0.00117	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GGT1—liver cancer	5.94e-05	0.00117	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—CYCS—liver cancer	5.88e-05	0.00116	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	5.75e-05	0.00114	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	5.75e-05	0.00114	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	5.74e-05	0.00113	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—PPARA—liver cancer	5.65e-05	0.00112	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—TP53—liver cancer	5.52e-05	0.00109	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	5.36e-05	0.00106	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	5.36e-05	0.00106	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTP1—liver cancer	5.33e-05	0.00105	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	5.31e-05	0.00105	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	5.26e-05	0.00104	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—HMOX1—liver cancer	5.11e-05	0.00101	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—IL6—liver cancer	5.05e-05	0.000999	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—liver cancer	5e-05	0.000989	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTM1—liver cancer	4.9e-05	0.000968	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	4.86e-05	0.00096	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	4.83e-05	0.000955	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	4.73e-05	0.000934	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP1A1—liver cancer	4.64e-05	0.000918	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	4.58e-05	0.000905	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	4.56e-05	0.000901	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	4.52e-05	0.000892	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN2A—liver cancer	4.47e-05	0.000884	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1B—liver cancer	4.43e-05	0.000876	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—liver cancer	4.23e-05	0.000835	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—ALB—liver cancer	4.2e-05	0.00083	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	4.13e-05	0.000817	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—liver cancer	4.09e-05	0.000808	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN1B—liver cancer	3.96e-05	0.000783	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—RAF1—liver cancer	3.8e-05	0.000751	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CCND1—liver cancer	3.78e-05	0.000747	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN1A—liver cancer	3.66e-05	0.000723	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	3.48e-05	0.000689	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—UGDH—liver cancer	3.47e-05	0.000687	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—MYC—liver cancer	3.39e-05	0.00067	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—EPT1—liver cancer	3.27e-05	0.000645	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—TAT—liver cancer	3.1e-05	0.000612	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	3.07e-05	0.000607	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.05e-05	0.000602	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—MYC—liver cancer	3.03e-05	0.000599	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	2.78e-05	0.000549	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—TP53—liver cancer	2.49e-05	0.000492	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.28e-05	0.00045	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CPT1B—liver cancer	2.1e-05	0.000416	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GLUL—liver cancer	2.1e-05	0.000416	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NR1H4—liver cancer	2.03e-05	0.000401	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTA3—liver cancer	2e-05	0.000394	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTA4—liver cancer	1.82e-05	0.000361	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.78e-05	0.000352	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTA2—liver cancer	1.78e-05	0.000351	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTA1—liver cancer	1.72e-05	0.000339	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NAT2—liver cancer	1.7e-05	0.000335	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.63e-05	0.000322	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ALDOB—liver cancer	1.63e-05	0.000321	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CRABP1—liver cancer	1.55e-05	0.000307	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.4e-05	0.000276	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—HPGDS—liver cancer	1.36e-05	0.000268	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.35e-05	0.000266	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.23e-05	0.000243	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.21e-05	0.00024	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PSMD10—liver cancer	1.21e-05	0.000239	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PSMA4—liver cancer	1.21e-05	0.000239	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GOT2—liver cancer	1.18e-05	0.000232	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP2E1—liver cancer	1.11e-05	0.000218	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.07e-05	0.000212	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYCS—liver cancer	1.03e-05	0.000204	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GGT1—liver cancer	1.02e-05	0.000201	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GOT1—liver cancer	1.02e-05	0.000201	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTP1—liver cancer	9.12e-06	0.00018	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—HMOX1—liver cancer	8.99e-06	0.000178	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTM1—liver cancer	8.38e-06	0.000166	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP1A1—liver cancer	7.94e-06	0.000157	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—MTHFR—liver cancer	7.4e-06	0.000146	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PPARA—liver cancer	7.26e-06	0.000144	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.53e-06	0.000129	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PIK3CG—liver cancer	6.22e-06	0.000123	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PPARG—liver cancer	6e-06	0.000119	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PIK3CD—liver cancer	5.47e-06	0.000108	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ALB—liver cancer	5.4e-06	0.000107	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PIK3CB—liver cancer	4.77e-06	9.42e-05	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PIK3CA—liver cancer	2.91e-06	5.74e-05	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—AKT1—liver cancer	2.37e-06	4.69e-05	CbGpPWpGaD
